Ventyx Biosciences, Inc. (VTYX): Price and Financial Metrics
VTYX Price/Volume Stats
| Current price | $1.72 | 52-week high | $11.48 |
| Prev. close | $1.78 | 52-week low | $1.72 |
| Day low | $1.72 | Volume | 1,237,900 |
| Day high | $1.82 | Avg. volume | 2,034,212 |
| 50-day MA | $2.20 | Dividend yield | N/A |
| 200-day MA | $3.56 | Market Cap | 121.62M |
VTYX Stock Price Chart Interactive Chart >
Ventyx Biosciences, Inc. (VTYX) Company Bio
Ventyx Biosciences, Inc., a clinical-stage biopharmaceutical company, develops small molecule product candidates for inflammatory diseases and autoimmune disorders. The company's lead product candidate is VTX958, a tyrosine kinase type 2 inhibitor that is in phase I clinical trials for the treatment of immune-mediated diseases, such as psoriasis, inflammatory bowel disease, psoriatic arthritis, and lupus. It also develops VTX002, an oral sphingosine 1 phosphate receptor 1 modulator that has completed phase I clinical trials for the treatment of ulcerative colitis; and VTX2735, a peripheral-targeted NOD-like receptor protein 3 (NLRP3) inflammasome inhibitor for the treatment of systemic inflammatory diseases, such as cardiovascular, hepatic, renal, and rheumatologic diseases. In addition, the company develops CNS-penetrant NLRP3 inhibitors. Ventyx Biosciences, Inc. was incorporated in 2018 and is based in Encinitas, California.
VTYX Price Returns
| 1-mo | -23.56% |
| 3-mo | -23.89% |
| 6-mo | -60.64% |
| 1-year | -27.43% |
| 3-year | -92.10% |
| 5-year | N/A |
| YTD | -30.36% |
| 2023 | -92.47% |
| 2022 | 65.11% |
| 2021 | N/A |
| 2020 | N/A |
| 2019 | N/A |
Loading social stream, please wait...